MedTrace Logo

Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer

NCT01086332 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-11-13

No results posted yet for this study

Summary

This study is designed to evaluate if nelfinavir works as a radiation sensitizer in combination with gemcitabine (a chemotherapy). We are also looking to establish the maximum dose of gemcitabine that is tolerated with the nelfinavir and radiation therapy, so the dose of gemcitabine is increased based on how previous trial participants tolerated their dose of gemcitabine.

Conditions

  • Pancreatic Neoplasms

Interventions

DRUG

Nelfinavir

1250 mg twice daily

DRUG

Gemcitabine

Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.

Sponsors & Collaborators

  • Holden Comprehensive Cancer Center

    collaborator OTHER

  • University of Iowa

    lead OTHER

Principal Investigators

  • Bryan G. Allen, M.D., PhD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-07-31
Completion
2015-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01086332 on ClinicalTrials.gov